CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Most Recent Articles

Hospital receives American Heart Association Get with The Guidelines-Stroke Gold Plus award for commitment to prioritizing quality care for stroke patients

As of September 12, 2022, Providence Mission Hospital Laguna Beach will close its Chemical Dependency program which is an elective inpatient and outpatient medical detoxification service for adults.

A new “Providence” sign was recently installed above the front entrance at Providence Santa Rosa Memorial Hospital.

Providence researcher awarded National Institutes of Health grant to lead a new lab focusing on the discovery of novel inflammatory pathways in cancer that are targets for therapeutic intervention.

Working toward health equity in our community

Dr. Shephal Doshi co-leads international clinical trial to evaluate Conformal Medical’s novel CLAAS implant

Learn about the health benefits of a traditional Asian diet at this free, online education event presented by Providence Cancer Institute and the Asian Health & Service Center.

When we talk about how Providence helps others, you might think first of health care for patients. But there are many more ways we support people in our communities.

Leading healthcare professionals interested in the treatment of patients with neuroendocrine tumors to gather in June for a comprehensive medical conference held in Oregon.

Although skin protection is important year-round, the summer is a good time to review helpful tips and tricks to help keep your skin safe while you enjoy the outdoors.

Two investigator-initiated trials sponsored by the Earle A. Chiles Research Institute are currently recruiting patients with either advanced HER2-positive or HR positive/HER2 negative breast cancer.

Minimally invasive technique allows for small, 5 mm incisions to remain hidden beneath the waistline

Providence researchers recruit adult patients with solid cancers for phase I clinical trial of genetically engineered, adoptively transferred T cells.

Providence St. Vincent Medical Center and Oregon Nurses Association labor negotiation teams are pleased to announce that we have have reached a tentative agreement.

The Children’s Hospital at Providence provides free immunization clinics for children 10 a.m.-1 p.m. on the first Saturday of each month in Providence Alaska Medical Center Suite A351 (A Tower).

Adoptive cell therapy study at Providence Cancer Institute gives hope to woman with metastatic pancreatic cancer. Results may lead to new treatments and longer lives for people with advanced cancers.

A Florida woman with advanced pancreatic cancer is hopeful after receiving an experimental treatment in a clinical trial at Providence Cancer Institute that shrunk her tumors.

In 2021, the Valdez Food Bank received $20,000 from Providence Alaska to add the Rental Deposit Assistance Program to its services.